Gene Vector
Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases.
est. 2017
PepGen
Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies.
64 employees · est. 2018 · Boston, United States
Gene Vector is the older company (2017 vs 2018).
Side-by-Side Comparison
| Metric | Gene Vector | PepGen |
|---|---|---|
| Founded | ||
| Founded | 2017 older | 2018 |
| Headquarters | ||
| Headquarters | Not tracked yet | Boston, United States |
| Employees | ||
| Employees | Not tracked yet | 64 |
| Industry | ||
| Industry | Biotechnology | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series A | IPO |
| Total Funding | ||
| Total Funding | $3.16M | $465.80M |
| Funding Rounds | ||
| Funding Rounds | 2 | 8 |
| Services | ||
| Services | Not tracked yet | development of disease-modifying therapies, conducting clinical trials, scientific research publications |
| Target Customers | ||
| Target Customers | Not tracked yet | patients with genetic neuromuscular diseases, patients with neurological diseases, medical professionals, healthcare providers |
| Taxonomy | ||
| Taxonomy | Gene Therapy, AAV Therapy, Ophthalmic Diseases, Neuromuscular Disorders, Genetic Diseases, Metabolic Diseases, Drug Development, Innovation, Biopharmaceuticals, Pharmaceuticals | Enhanced Delivery Oligonucleotide (EDO) Platform, Disease-modifying Therapies, Genetic Neuromuscular Disorders, Neurological Disorders, Nucleic Acid Therapeutics, Antisense Oligonucleotides, Conjugate Therapeutics, Drug Delivery Technologies, Therapeutics Development, Proprietary Drug Platforms, Genetic Disorders, Neuromuscular Diseases, Precision Medicine, Innovative Drug Solutions |
| Website | ||
| Website | jwksw.com | pepgen.com |
About Gene Vector
Gene Vector is a biotechnology company that is dedicated to advancing the development of novel adeno-associated virus (AAV) gene therapy drugs. Founded in 2017, the company is at the forefront of pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases...
About PepGen
PepGen, founded in 2018, is a burgeoning player in the Biotechnology industry, headquartered in the United States. The company is on a mission to revolutionize treatment options for genetic neuromuscular and neurological disorders through its proprietary Enhanced Delivery Oligonucleotide (EDO) platf...
We will tell you when either one moves
BounceWatch watches Gene Vector and PepGen for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Gene Vector and PepGen — by email.
Frequently Asked Questions
Compare Gene Vector with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Gene Vector on 12 Sep 2024, and PepGen on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.